Dendreon to Host Conference Call on October 30 to Announce Third Quarter Financial Results and Webcast Presentations at Upcoming Conferences
October 5, 2012—Dendreon Corporation (Nasdaq:DNDN) today announced that
management will host a conference call on Tuesday, October 30, 2012, at
9:00 a.m. ET to review third quarter financial results.
Access to the discussion may be obtained as follows:
9:00 a.m. ET / 6:00 a.m. PT
October 30, 2012
1-877-548-9590 (domestic) or +1-720-545-0037 (international)
conference pass code: 38408702
(homepage and investor relations section)
A recorded rebroadcast will be available for interested parties unable
to participate in the live conference call by dialing 1-800-585-8367 or
+1-404-537-3406 for international callers; the conference ID number is
38408702. The replay will be available from 12:00 p.m. ET on Tuesday,
October 30, until 11:59 p.m. ET on Tuesday, November 6. In addition, the
webcast will be archived for on-demand listening for 90 days at www.dendreon.com.
Dendreon Corporation also announced that management will present at the
Lazard Capital Markets 9th Annual Healthcare Conference in New York
City, on November 13, 2012, at 1:00 p.m. ET
Credit Suisse 2012 Healthcare Conference in Phoenix, AZ, on November
15, 2012, at 3:30 p.m. MST
The presentations will be audio webcast live and available for replay
from Dendreon's website, www.dendreon.com.
If you are unable to listen to the live webcasts, they will be archived
on the site following the presentation. To access the replays, go to the
Investor Relations section of the website.
Dendreon Corporation is a biotechnology company whose mission is to
target cancer and transform lives through the discovery, development,
commercialization and manufacturing of novel therapeutics. The Company
applies its expertise in antigen identification, engineering and cell
processing to produce active cellular immunotherapy (ACI) product
candidates designed to stimulate an immune response in a variety of
tumor types. Dendreon's first product, PROVENGE® (sipuleucel-T), was
approved by the U.S. Food and Drug Administration (FDA) in April 2010.
Dendreon is exploring the application of additional ACI product
candidates and small molecules for the potential treatment of a variety
of cancers. The Company is headquartered in Seattle, Washington, and is
traded on the NASDAQ Global Market under the symbol DNDN. For more
information about the Company and its programs, visit http://www.dendreon.com/.
Source: Dendreon Corporation
News Provided by Acquire Media
Close window | Back to top